James Sullivan
Technik-/Wissenschafts-/F&E-Leiter bei ENGENE HOLDINGS INC.
Profil
James C.
Sullivan is currently the Chief Scientific Officer at enGene Holdings, Inc. since 2023 and at enGene, Inc. since 2022.
Previously, he served as the Executive Director & Head-Translational Biology at Sana Biotechnology, Inc. from 2019 to 2021 and as the Senior Vice President-Pulmonary Discovery at Translate Bio, Inc. in 2021 to 2022.
He holds a doctorate degree from Boston University, an undergraduate degree from Boston College, and a graduate degree from University College Dublin.
Aktive Positionen von James Sullivan
| Unternehmen | Position | Beginn |
|---|---|---|
| ENGENE HOLDINGS INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.11.2023 |
enGene, Inc.
 enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Technik-/Wissenschafts-/F&E-Leiter | 01.02.2022 |
Ehemalige bekannte Positionen von James Sullivan
| Unternehmen | Position | Ende |
|---|---|---|
| TRANSLATE BIO, INC. | Corporate Officer/Principal | 01.02.2022 |
| SANA BIOTECHNOLOGY, INC. | Direktor/Vorstandsmitglied | 01.01.2021 |
Ausbildung von James Sullivan
| Boston College | Undergraduate Degree |
| University College Dublin | Graduate Degree |
| Boston University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| SANA BIOTECHNOLOGY, INC. | Health Technology |
| ENGENE HOLDINGS INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Translate Bio, Inc.
 Translate Bio, Inc. BiotechnologyHealth Technology Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidate, MRT5005 is designed for the treatment of cystic fibrosis. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA. | Health Technology |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Health Technology |
